verbrinacogene setparvovec
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 5, 2017 (NCT03369444)
Timeline
Indications
Studied for
Mechanism of action
- Coagulation factor IXSupplementation
F9 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650247 ↗
Also known as
- flt180a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05164471 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Freeline Therapeutics |
| NCT03641703 | Phase 2/Phase 3 (Phase 3) | Jul 10, 2018 | Freeline Therapeutics |
| NCT03369444 | Phase 1 | Dec 5, 2017 | University of London |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Freeline Therapeutics | For profit | 2 | 2 | 2 | 2018 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1